Lee Ji Hyun, Kang Kyung Woo, Kim Jeong-Eun, Hwang Sang Won, Park Jae Hong, Kim Seok-Hyun, Ji Jun Ho, Kim Tae Gyu, Nam Hyun-Yeol, Roh Mee Sook, Lee Eun Hee, Park Moon-Il, Kim Mee-Seon, Lee Hyoun Wook
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon, South Korea.
Department of Cardiovascular and Thoracic Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon, South Korea.
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9487-93. eCollection 2015.
Heat shock protein 90 (HSP90), a molecular chaperone, plays important roles in cellular protection against various stressful stimuli and in the regulation of cellular growth and apoptosis. HSP90 has 4 different types of human isoforms; HSP90α, HSP90β, glucose related protein 94 (GRP94) and tumor necrosis factor (TNF) receptor-associated protein 1 (TRAP1). We assessed the differential expression of these HSP90 isoforms in small-cell lung cancer (SCLC) and the correlation of their expression levels with clinicopathological factors and patient survival rates. This study included 117 SCLCs, comprised of 108 primary and 9 metastatic tumor tissues. We performed immunohistochemical staining for HSP90α, HSP90β, GRP94 and TRAP1 in 117 tumors and found that HSP90α and HSP90β were positive in 11 (9%) and 61 tumors (52%), respectively, most of which showed weak expression, whereas GRP94 and TRAP1 were positive in 115 (98%) and 117 tumors (100%), respectively, the majority of which showed moderate or strong expression. None of the HSP90 isoforms showed significant associations with clinicopathological factors or survival status in patients with SCLC. Our results indicate that GRP94 and TRAP1 might contribute more to the carcinogenesis or biology of SCLC than HSP90α and HSP90β, and that isoform selectivity should be considered when HSP90 inhibitors are studied or utilized for the treatment of SCLC.
热休克蛋白90(HSP90)作为一种分子伴侣,在细胞抵御各种应激刺激以及细胞生长和凋亡的调节中发挥着重要作用。HSP90有4种不同类型的人类异构体;HSP90α、HSP90β、葡萄糖相关蛋白94(GRP94)和肿瘤坏死因子(TNF)受体相关蛋白1(TRAP1)。我们评估了这些HSP90异构体在小细胞肺癌(SCLC)中的差异表达,以及它们的表达水平与临床病理因素和患者生存率的相关性。本研究纳入了117例SCLC,包括108例原发性肿瘤组织和9例转移瘤组织。我们对117例肿瘤进行了HSP90α、HSP90β、GRP94和TRAP1的免疫组织化学染色,发现HSP90α和HSP90β分别在11例(9%)和61例肿瘤(52%)中呈阳性,其中大多数表现为弱表达,而GRP94和TRAP1分别在115例(98%)和117例肿瘤(100%)中呈阳性,其中大多数表现为中度或强表达。在SCLC患者中,没有一种HSP90异构体与临床病理因素或生存状况显示出显著相关性。我们的结果表明,与HSP90α和HSP90β相比,GRP94和TRAP1可能对SCLC的致癌作用或生物学特性贡献更大,并且在研究或使用HSP90抑制剂治疗SCLC时应考虑异构体的选择性。